GLORIA

GEOMAR Library Ocean Research Information Access

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
  • 1
    In: Journal of Immunotherapy, Ovid Technologies (Wolters Kluwer Health), Vol. 34, No. 2 ( 2011-03), p. 165-174
    Type of Medium: Online Resource
    ISSN: 1524-9557
    Language: English
    Publisher: Ovid Technologies (Wolters Kluwer Health)
    Publication Date: 2011
    detail.hit.zdb_id: 2048797-6
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 2
    In: Blood, American Society of Hematology, Vol. 124, No. 21 ( 2014-12-06), p. 3832-3832
    Abstract: Therapeutic reactivity of CD20-specific monoclonal antibodies (mAb) or CD19-specific chimeric antigen receptor (CAR)-transduced T cells is exerted by targeting extracellular antigens. However, loss of CD20 and CD19 expression or absence of these molecules on other malignancies such as multiple myeloma restricts their application. Here, we identified the intracellular transcription factor Bob1 encoded by gene POU2AF1 as a suitable target for immunotherapy. Bob1 is highly expressed in CD19+ B cells, acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL) and multiple myeloma (MM) and is absent in the non-B lineages including CD34+ hematopoietic progenitor cells (HPCs), T cells, fibroblasts, keratinocytes and gastrointestinal tract. Bob1 is localized intracellularly but HLA-presented Bob1-derived peptides are accessible on the cell surface to T cell receptors (TCRs) and can thus be recognized by T cells. From the HLA-presented ligandome (Mol Cell Proteomics, 2013;12:1829) we identified naturally processed Bob1-derived peptides displayed in HLA-A*0201 (HLA-A2) and in HLA-B*0702 (HLA-B7). Since auto-reactivity towards self-antigens such as Bob1 is prevented by depleting high-avidity T cells recognizing self-antigens in self-HLA, we exploited the immunogenicity of these peptides presented in allogeneic HLA. From a total of 3 x 109 peripheral blood mononuclear cells from 6 different HLA-A2/B7-negative healthy donors, we isolated and clonally expanded more than 1000 CD8+ T cells binding to peptide-MHC-tetramers composed of the Bob1-derived peptides bound to HLA-A2 or HLA-B7. The T cell clones were tested for stringent peptide-specificity by stimulation with Bob1-negative K562 cells expressing either HLA-A2 or B7 unloaded or pulsed with Bob1-derived peptides. This resulted in the selection of 15 T cell clones highly specific for Bob1. To identify the T cell clones of highest avidity, T cell clones were compared for peptide-sensitivity by testing the recognition of stimulator cells loaded with titrated amounts of Bob1-derived peptides and of Bob1-expressing HLA-A2/B7-positive EBV-transformed B cells. T cell clone 4G11 was selected because of high sensitivity and specificity for Bob1-derived peptide Bob144 presented in HLA-B7 and T cell clone 3C10 specifically recognized peptide Bob1245 bound to HLA-A2. Bob1-dependent recognition was demonstrated by transduction of Bob1 into cell lines that otherwise lack Bob1 expression. To investigate whether harmful toxicities could be caused by these T cell clones, we tested their reactivity against a wide panel of Bob1-negative stimulator cells demonstrating absence of recognition of HLA-B7-positive CD34+ HPCs, T cells, monocytes, immature and mature dendritic cells, and fibroblasts even under simulated inflamed conditions. Stringent HLA-B7-restricted recognition was observed for clone 4G11 when tested against a stimulator panel expressing a wide range of common and rare HLA class I and II molecules. These data illustrate a safe reactivity profile with little chance of off-target toxicity. To test their clinical applicability, clone 4G11 and 3C10 were tested for recognition of various primary B cell malignancies. Clone 4G11 efficiently recognized HLA-B7-positive primary ALL, CLL and mantle cell lymphoma while clone 3C10 recognized HLA-A2-positive primary B cell malignancies albeit to a lesser degree. Furthermore, reproducible strong recognition of purified primary HLA-B7-positive multiple myeloma could be demonstrated for clone 4G11. Therefore, T cell clone 4G11’s TCR may be used for immunotherapy by administering TCR-transduced T cells to multiple myeloma patients. To test whether introduction of 4G11’s TCR confers Bob1-reactivity onto recipient cells, the TCR was cloned into a retroviral vector. Highly specific reactivity against HLA-B7-positive Bob1-expressing target cells could be installed to TCR-transduced recipient T cells. In summary, we identified the intracellular transcription factor Bob1 encoded by gene POU2AF1 as a suitable target for TCR-based immunotherapies of B cell malignancies and multiple myeloma. Bob1-specific T cell clone 4G11 efficiently recognized primary B cell leukemia and multiple myeloma. TCR gene transfer approaches using Bob1-specific TCRs can bring novel treatment modalities for patients with B cell malignancies or multiple myeloma. Disclosures No relevant conflicts of interest to declare.
    Type of Medium: Online Resource
    ISSN: 0006-4971 , 1528-0020
    RVK:
    RVK:
    Language: English
    Publisher: American Society of Hematology
    Publication Date: 2014
    detail.hit.zdb_id: 1468538-3
    detail.hit.zdb_id: 80069-7
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 3
    In: Blood, American Society of Hematology, Vol. 118, No. 21 ( 2011-11-18), p. 3008-3008
    Abstract: Abstract 3008 Invasive aspergillosis is a common and life-threatening complication in recipients of allogeneic stem cell transplantation (SCT). Patients are most severely at risk in the neutropenic phase, but there is increasing evidence that impaired T cell mediated immunity also increases the risk of invasive aspergillosis. In healthy individuals we identified Aspergillus -specific T cells by measuring IFN γ production in response to stimulation with overlapping peptides of the A. fumigatus proteins Crf1 and Catalase1. Antigen specific CD4+ T cells were single cell sorted to identify the recognized epitope and Aspergillus specificity was confirmed, based on reactivity to dendritic cells loaded with Aspergillus crude extract. Further characterization of the T cell mediated immune response against A. fumigatus is crucial for the development of new therapeutic strategies including adoptive transfer of antigen specific T cells. To investigate the role of Aspergillus -specific T cells in the clearance of aspergillus infection, we analyzed the T cell mediated immune response against A. fumigatus in patients who recovered from invasive aspergillosis. All patients had received an allogeneic SCT because of a hematological malignancy and aspergillus infection was diagnosed 4 to 5 months after SCT. At 4 time points after the diagnosis of invasive aspergillosis the T cell mediated immune response was analyzed. Peripheral blood mononuclear cells (PBMC) of patients who recovered from invasive aspergillosis were stimulated with the overlapping peptides of Crf1 and Catalase1. Directly ex vivo no Aspergillus -specific T cells could be detected by intracellular staining for IFN γ and CD154. However, when PBMC were stimulated with the peptide mixtures of Crf1 and Catalase1, cultured for 7 days in the presence of IL-2 and restimulated with Crf1 and Catalase1 we detected clear populations of Aspergillus -specific T cells in 3 of the 4 analyzed patients. In one patient 3% Crf1-specific and 1.7% Catalase1-specific CD154-expressing CD4+ T cells were shown 1 week after aspergillosis was diagnosed, coinciding with a rapid improvement of the infection with a clear regression of the pulmonary lesions. Up to 45% of the activated T cells produced IFN γ. After resolution of the infection, a decline in the percentage of activated and IFN γ producing T cells was observed, with a low percentage of 0.2% Aspergillus -specific CD4+ T cells persisting 3 years after the clearance of invasive aspergillosis. Two other patients were treated for aspergillosis for a long time, because of a prolonged period of leucopenia. Both were treated with prednisolone, one for GvHD, the other for auto-immune hemolytic anemia and granulocytopenia. The first patient had a mixed radiological response with a decline in the number of peribronchial infiltrates and a newly arisen nodular lesion 3 months after diagnosis, which was stable in size in the following 6 months. During this period no Aspergillus -specific T cells could be detected. After 1 year, 3 months after recovery of the leukocyte count, low numbers of Catalase1-specific CD4+ T cells were present coinciding with regression of the nodular lesion. Both Catalase1-specific (1%) and Crf1-specific (0.3%) CD4+ T cells could be shown 21 months after initial diagnosis, when the nodular lesion was still present, but declining in size. In the other patient 0.1 % Crf1-specific CD4+ T cells were detected during the whole period of Voriconazole treatment. One year after restoration of normal leukocyte counts and clearance of the aspergillus infection 0.65% Crf1-specific CD4+ T cells were present, but no Catalase1-specific T cells could be shown. In conclusion, using only 2 A. fumigatus proteins as target antigens, we have demonstrated the development of Aspergillus -specific T cells in 3 out of 4 patients, coinciding with the decline of aspergillus lesions. These data indicate that an immune response directed against A. fumigatus proteins helps to clear an aspergillus infection. Therefore, Aspergillus -specific T cells generated in vitro by stimulating with A. fumigatus proteins like Crf1 and Catalase1, may be used for adoptive T cell therapy for invasive aspergillosis. Disclosures: No relevant conflicts of interest to declare.
    Type of Medium: Online Resource
    ISSN: 0006-4971 , 1528-0020
    RVK:
    RVK:
    Language: English
    Publisher: American Society of Hematology
    Publication Date: 2011
    detail.hit.zdb_id: 1468538-3
    detail.hit.zdb_id: 80069-7
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 4
    In: Biology of Blood and Marrow Transplantation, Elsevier BV, Vol. 20, No. 5 ( 2014-05), p. 655-661
    Type of Medium: Online Resource
    ISSN: 1083-8791
    Language: English
    Publisher: Elsevier BV
    Publication Date: 2014
    detail.hit.zdb_id: 3056525-X
    detail.hit.zdb_id: 2057605-5
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 5
    In: Journal of Experimental Medicine, Rockefeller University Press, Vol. 211, No. 13 ( 2014-12-15), p. 2599-2615
    Abstract: αβ and γδ T cells are disparate T cell lineages that can respond to distinct antigens (Ags) via the use of the αβ and γδ T cell Ag receptors (TCRs), respectively. Here we characterize a population of human T cells, which we term δ/αβ T cells, expressing TCRs comprised of a TCR-δ variable gene (Vδ1) fused to joining α and constant α domains, paired with an array of TCR-β chains. We demonstrate that these cells, which represent ∼50% of all Vδ1+ human T cells, can recognize peptide- and lipid-based Ags presented by human leukocyte antigen (HLA) and CD1d, respectively. Similar to type I natural killer T (NKT) cells, CD1d-lipid Ag-reactive δ/αβ T cells recognized α-galactosylceramide (α-GalCer); however, their fine specificity for other lipid Ags presented by CD1d, such as α-glucosylceramide, was distinct from type I NKT cells. Thus, δ/αβTCRs contribute new patterns of Ag specificity to the human immune system. Furthermore, we provide the molecular bases of how δ/αβTCRs bind to their targets, with the Vδ1-encoded region providing a major contribution to δ/αβTCR binding. Our findings highlight how components from αβ and γδTCR gene loci can recombine to confer Ag specificity, thus expanding our understanding of T cell biology and TCR diversity.
    Type of Medium: Online Resource
    ISSN: 1540-9538 , 0022-1007
    RVK:
    Language: English
    Publisher: Rockefeller University Press
    Publication Date: 2014
    detail.hit.zdb_id: 1477240-1
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 6
    In: Biology of Blood and Marrow Transplantation, Elsevier BV, Vol. 18, No. 2 ( 2012-02), p. 210-219
    Type of Medium: Online Resource
    ISSN: 1083-8791
    Language: English
    Publisher: Elsevier BV
    Publication Date: 2012
    detail.hit.zdb_id: 3056525-X
    detail.hit.zdb_id: 2057605-5
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 7
    In: Molecular & Cellular Proteomics, Elsevier BV, Vol. 12, No. 7 ( 2013-07), p. 1829-1843
    Type of Medium: Online Resource
    ISSN: 1535-9476
    Language: English
    Publisher: Elsevier BV
    Publication Date: 2013
    detail.hit.zdb_id: 2071375-7
    SSG: 12
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 8
    In: Blood, American Society of Hematology, Vol. 122, No. 21 ( 2013-11-15), p. 3295-3295
    Abstract: Cytomegalovirus (CMV) reactivation frequently occurs during early immune reconstitution after hematopoietic stem cell transplantation (HSCT). Although CMV is associated with accelerated immune ageing in healthy individuals, the impact of early CMV reactivation on T-cell immunity long term post HSCT is unknown. In this study, we report the impact of early CMV reactivations on the reconstitution and composition of the T-lymphocyte compartment one to two year after HSCT in a large cohort of pediatric HSCT recipients. Methods We analyzed the lymphocyte compartment one and two year after transplantation in 131 consecutive (2002 - 2011) pediatric HSCT recipients that were eligible for follow up one year post HSCT. Viral infections were routinely monitored by weekly serum viral DNA PCR in the first 100 days. Peripheral blood mononuclear cells were routinely analyzed by multicolor flow cytometry. Six patients with early CMV reactivation and an HLA type for which CMV-tetramers were available were analyzed for the presence and phenotype of CMV-specific CD8+ T-lymphocytes. Results One year post HSCT, patients with early CMV reactivation (n = 46, PCR ≥ 1x ≥ 200 copies / mL) had significantly higher lymphocyte counts compared to patients without CMV reactivation (n = 85, PCR always 〈 200 copies / mL). This could be attributed to a significant increase of CD3+ T-lymphocytes while NK- and B-cell numbers did not differ. Within the T-cell compartment, a three-fold expansion of CD8+ T-cells (median 1323 vs. 424 cells / μL, p 〈 0.0001, Mann-Whitney) and an increase in gamma-delta T-cells (median 104 vs. 47 cells / μL, p = 0.0005) was observed, while absolute numbers of CD4+ T-cells did not differ between the groups. This effect was not observed in relation to Epstein-Barr virus (EBV) or Adenovirus (HAdV) reactivation. In multivariate analysis, CD8+ T-cell numbers one year post HSCT were highly influenced by CMV reactivation (p 〈 0.0001, linear regression) but not affected by pre-transplant CMV serostatus of donor (p = 0.22) or recipient (p = 0.14). In a representative subcohort (n = 53, 2008 - 2010), we more closely analyzed the differentiation stages of T-cells based on expression of CD45RA and CCR7. In both the CD4+ and CD8+T-cell subset, the proportion of Effector Memory (EM) and EMRA T-cells was enlarged in patients with (n = 18) compared to patients without (n = 35) early CMV reactivation. In the CD8+ T-cell compartment, this was caused by a major expansion of CD8+ EM and EMRA T-cells (median 485 vs. 141, p 〈 0.0001 and 509 vs. 114 cells / μL, p 〈 0.0001, Figure A), while the Naive (median 105 vs. 169 cells / μL, p = 0.17) and Central Memory (CM) compartment did not differ. In the CD4+ compartment, a non-significant increase of EM and EMRA cells was accompanied by a non-significant decrease of N and CM cells. CMV-specific CD8+ T-cells (median 4.1, range 0.3 - 25.6% of CD8+ T-cells) were detected within the EM and EMRA compartment. Two year after HSCT, data were available for 76 patients. Both in patients with (lymphocyte subsets: n = 34 / T-cell differentiation: n = 12) and without (n = 42 / n = 19) early CMV reactivation, a further reconstitution of CD4+ and CD8+ T-cells was observed, reflected by an expansion of Naive and CM cells (Figure B). However, the total number of CD8+ T-cells decreased in patients with early CMV reactivation, caused by a contraction of late differentiated CD8+ EM and EMRA cells (median 825 to 618, p = 0.0068 and 555 to 378 cells / μL, p = 0.0342, Wilcoxon). Conclusion Early CMV reactivation leaves a virus-specific and dynamic imprint on the reconstituting immune system 1 and 2 year after HSCT. The marked expansion of CD8 + EM and EMRA T-cells was not seen in patients with early EBV or HAdV reactivation and did not compromise the reconstitution of the Naive and CM compartment available to respond to neo- and recall antigens. Pediatric HSCT recipients differed from solid organ transplantation recipients in which CMV has been correlated to an accelerated and ongoing accumulation of late differentiated T-cells. The dynamic contraction of the CD8+ late differentiated memory T-cell compartment in the second year after HSCT implies that an ongoing process of immune-regulation and further reconstitution is modeling the cellular immune system after discontinuation of immunosuppressive medication. Disclosures: No relevant conflicts of interest to declare.
    Type of Medium: Online Resource
    ISSN: 0006-4971 , 1528-0020
    RVK:
    RVK:
    Language: English
    Publisher: American Society of Hematology
    Publication Date: 2013
    detail.hit.zdb_id: 1468538-3
    detail.hit.zdb_id: 80069-7
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 9
    In: Clinical Cancer Research, American Association for Cancer Research (AACR), Vol. 17, No. 17 ( 2011-09-01), p. 5615-5625
    Abstract: Purpose: In human leukocyte antigen (HLA)–matched stem cell transplantation (SCT), it has been shown that beneficial immune response mediating graft-versus-tumor (GVT) responses can be separated from graft-versus-host disease (GVHD) immune responses. In this study, we investigated whether it would be possible to dissect the beneficial immune response of allo-HLA–reactive T cells with potent antitumor reactivity from GVHD-inducing T cells present in the detrimental immune response after HLA-mismatched SCT. Experimental Design: The presence of specific tumor-reactive T cells in the allo-HLA repertoire was analyzed at the time of severe GVHD after HLA-mismatched SCT, using tetramers composed of different tumor-associated antigens (TAA). Results: High-avidity allo-HLA-restricted T cells specific for the TAA preferentially expressed antigen on melanomas (PRAME) were identified that exerted highly single-peptide–specific reactivity. The T cells recognized multiple different tumor cell lines and leukemic cells, whereas no reactivity against a large panel of nonmalignant cells was observed. These T cells, however, also exerted low reactivity against mature dendritic cells (DC) and kidney epithelial cells, which was shown to be because of low PRAME expression. Conclusions: On the basis of potential beneficial specificity and high reactivity, the T-cell receptors of these PRAME-specific T cells may be effective tools for adoptive T-cell therapy. Clinical studies have to determine the significance of the reactivity observed against mature DCs and kidney epithelial cells. Clin Cancer Res; 17(17); 5615–25. ©2011 AACR.
    Type of Medium: Online Resource
    ISSN: 1078-0432 , 1557-3265
    RVK:
    Language: English
    Publisher: American Association for Cancer Research (AACR)
    Publication Date: 2011
    detail.hit.zdb_id: 1225457-5
    detail.hit.zdb_id: 2036787-9
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 10
    In: Blood, American Society of Hematology, Vol. 116, No. 21 ( 2010-11-19), p. 2332-2332
    Abstract: Abstract 2332 Invasive aspergillosis is a common and life-threatening complication in recipients of allogeneic stem cell transplantation. Patients are at risk in the neutropenic phase, but also after recovery of the neutrophil count there is an increased risk of developing invasive aspergillosis, probably caused by other defects in the innate immune system, or by impaired T cell mediated immunity after stem cell transplantation. In healthy individuals and in patients lymphoproliferative responses to crude Aspergillus extracts and recombinant antigens have been shown. Furthermore, patients after haploidentical stem cell transplantation were less susceptible to aspergillus infection when transferred with T cell lines generated against Aspergillus fumigatus. To facilitate the study of the role of T cell mediated immunity in aspergillus infection and develop new therapeutic strategies to prevent or treat invasive aspergillosis we aimed to identify T cell epitopes of Aspergillus fumigatus. Peripheral blood mononuclear cells (PBMC) of healthy individuals were stimulated with overlapping 15mer peptides of the Aspergillus fumigatus proteins Crf1 and Catalase1. Directly after stimulation no antigen specific T cells could be detected, however after stimulation with the complete peptide pool, IL-2 and IL-15 for 7 days and subsequent restimulation with peptide pulsed autologous PBMC an increase of activated T cells could be detected in half of the healthy donors, based on IFNγ production, CD154 (CD40 ligand) and CD137 expression. From 6 donors antigen specific CD4+ T cells were single cell sorted 4 hours after restimulation with the complete peptide pool using the IFNγ capture assay or by sorting the CD137+ CD4+ T cells 48 hours after restimulation with the complete peptide pool and cells were clonally expanded. The generated T cell clones were tested for Aspergillus peptide specificity against the complete peptide pool using ELISA to determine the IFNy and IL-4 production. Aspergillus peptide specific clones were further analyzed with subpools of the overlapping peptides, to identify the specific T cell epitope. These subpools are organized in a matrix to enable us to identify the recognized epitope directly from this analysis. Subsequently, the T cell clones were stimulated with the single recognized peptides to confirm the identified epitopes. Five different T cell epitopes of Crf1 were identified: one epitope at position 161–171, which was previously described, and four novel epitopes. For the Catalase1 protein we identified 7 different epitopes, which have not been described before. By using HLA-blocking monoclonal antibodies and an HLA-typed EBV-LCL panel we determined the HLA-restriction of the different T cell epitopes. Two Crf1 epitopes and three Catalase1 epitopes were HLA-DR restricted, and one of the Crf1 epitopes was presented by HLA-DP. The HLA-restriction of the other 6 identified epitopes has not yet been characterized. The T cell clones showed 3 different patterns of cytokine production. Some clones only produced IFNγ, some clones only IL-4 and others produced both IFNγ and IL-4. Twelve T cell epitopes in two different proteins of Aspergillus fumigatus, presented by various HLA class II molecules, were identified. The generated T cell clones showed a variable pattern of cytokine production. To evaluate whether all these epitopes are relevant for the immune response against aspergillosis, the specificity against Aspergillus fumigatus will be tested by incubating T cells and dendritic cells with inactivated fungus. If Aspergillus-specificity is demonstrated, these epitopes can be used to study T cell mediated immunity in patients with aspergillosis and be a first step towards new therapeutic options for invasive aspergillosis. Disclosures: No relevant conflicts of interest to declare.
    Type of Medium: Online Resource
    ISSN: 0006-4971 , 1528-0020
    RVK:
    RVK:
    Language: English
    Publisher: American Society of Hematology
    Publication Date: 2010
    detail.hit.zdb_id: 1468538-3
    detail.hit.zdb_id: 80069-7
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...